Plasma concentrations of adrenomedullin and natriuretic peptides in patients with essential hypertension

Hu,Wei; Zhou,Pang‑Hu; Zhang,Xiao‑Bin; Xu,Chang‑Geng; Wang,Wei

doi:10.3892/etm.2015.2345

Plasma concentrations of adrenomedullin and natriuretic peptides in patients with essential hypertension

Authors:
- Wei Hu
- Pang‑Hu Zhou
- Xiao‑Bin Zhang
- Chang‑Geng Xu
- Wei Wang
View Affiliations

Affiliations: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: March 11, 2015 https://doi.org/10.3892/etm.2015.2345
Pages: 1901-1908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to assess any changes in the plasma concentrations of adrenomedullin (ADM) and atrial and brain natriuretic peptide (ANP and BNP, respectively), and to investigate their pathophysiological roles in patients with essential hypertension (EH). The plasma ADM, ANP and BNP concentrations were measured in 64 patients with untreated EH and 35 normotensive control subjects. After 4 weeks of effective antihypertensive therapy with oral drugs for the hypertensive patients, the plasma concentrations of ADM, ANP and BNP in the hypertensive patients were measured again. The plasma concentrations of ADM, ANP and BNP were significantly higher in the hypertensive patients than those in the control subjects, and the concentrations increased with the clinical stage. Furthermore, the hypertensive patients exhibited increased mean arterial pressure (MAP), blood urea nitrogen (BUN), serum creatinine (Scr) and decreased glomerular filtration rates (GFRs) compared with the control subjects. The plasma ADM concentration was not only correlated with BUN, Scr and the GFR, but was also associated with the MAP and the plasma levels of ANP and BNP. Following effective antihypertensive therapy with oral medication for 4 weeks, the plasma concentrations of ADM, ANP and BNP were significantly, but not sharply, decreased. In conclusion, ADM, along with ANP and BNP, may be involved in the mechanisms acting against a further increase in blood pressure and may be useful biomarkers for the diagnosis and treatment of hypertensive patients.

View Figures

View References

1	Kitamura K, Kangawa K, Kawamoto M, et al: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 192:553–560. 1993. View Article : Google Scholar : PubMed/NCBI
2	Hay DL, Walker CS and Poyner DR: Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: Opportunities and challenges. Endocr Relat Cancer. 18:C1–C14. 2010. View Article : Google Scholar : PubMed/NCBI
3	Beltowski J and Jamroz A: Adrenomedullin - what do we know 10 years since its discovery? Pol J Pharmacol. 56:5–27. 2004.PubMed/NCBI
4	Eto T: A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides. 22:1693–1711. 2001. View Article : Google Scholar : PubMed/NCBI
5	Kato J, Kitamura K, Matsui E, et al: Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 22:61–65. 1999. View Article : Google Scholar : PubMed/NCBI
6	Ishimitsu T, Ono H, Minami J and Matsuoka H: Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther. 111:909–927. 2006. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Jiang C, Wang X, Zhang Y, Shibahara S and Takahashi K: Adrenomedullin is a novel adipokine: Adrenomedullin in adipocytes and adipose tissues. Peptides. 28:1129–1143. 2007. View Article : Google Scholar : PubMed/NCBI
8	Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM and Nicholls MG: Hemodynamic, hormonal and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab. 85:1016–1020. 2000. View Article : Google Scholar : PubMed/NCBI
9	Szokodi I, Kinnunen P and Ruskoaho H: Inotropic effect of adrenomedullin in the isolated perfused rat heart. Acta Physiol Scand. 156:151–152. 1996. View Article : Google Scholar : PubMed/NCBI
10	Federico C: Natriuretic Peptide system and cardiovascular disease. Heart Views. 11:10–15. 2010.PubMed/NCBI
11	Kitamura K and Eto T: Adrenomedullin - physiological regulator of the cardiovascular system or biochemical curiosity? Curr Opin Nephrol Hypertens. 6:80–87. 1997. View Article : Google Scholar : PubMed/NCBI
12	Herget-Rosenthal S, Bökenkamp A and Hofmann W: How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem. 40:153–161. 2007. View Article : Google Scholar : PubMed/NCBI
13	Whitworth JA; World Health Organiztion, ; International Society of Hypertension Writing Group, : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 21:1983–1992. 2003. View Article : Google Scholar : PubMed/NCBI
14	Kitamura K, Ichiki Y, Tanaka M, et al: Immunoreactive adrenomedullin in human plasma. FEBS Lett. 341:288–290. 1994. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Zhou Y, Meng L, Lu X, Ou N and Li X: Inflammatory mediators in Chinese patients with congestive heart failure. J Clin Pharmacol. 49:591–599. 2009. View Article : Google Scholar : PubMed/NCBI
16	Cheung BM and Tang F: Adrenomedullin: Exciting new horizons. Recent Pat Endocr Metab Immune Drug Discov. 6:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
17	Suzuki Y, Horio T, Hayashi T, et al: Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Regul Pept. 118:99–104. 2004. View Article : Google Scholar : PubMed/NCBI
18	Kato J, Kitamura K and Eto T: Plasma adrenomedullin level and development of hypertension. J Hum Hypertens. 20:566–570. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kato J, Tsuruda T, Kita T, Kitamura K and Eto T: Adrenomedullin: A protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 25:2480–2487. 2005. View Article : Google Scholar : PubMed/NCBI
20	Tsuruda T, Kato J, Hatakeyama K, et al: Antifibrotic effect of adrenomedullin on coronary adventitia in angiotensin II-induced hypertensive rats. Cardiovasc Res. 65:921–929. 2005. View Article : Google Scholar : PubMed/NCBI
21	Irzmański R, Pawlicki L, Charłusz M and Kowalski J: Concentration of natriuretic peptides in patients suffering from idiopathic arterial hypertension and left ventricular diastolic dysfunction confirmed by echocardiography. Clin Exp Hypertens. 34:530–540. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kohno M, Hanehira T, Kano H, et al: Plasma adrenomedullin concentrations in essential hypertension. Hypertension. 27:102–107. 1996. View Article : Google Scholar : PubMed/NCBI
23	Kong DG, Gao H, Lu YQ, et al: Anxiety disorders are associated with increased plasma adrenomedullin level and left ventricular hypertrophy in patients with hypertension. Clin Exp Hypertens. 36:27–31. 2013. View Article : Google Scholar : PubMed/NCBI
24	Grzywa-Celińska A, Celiński R, Kwaśniewska K, Dyczko M, Prystupa A and Mosiewicz J: The usefulness of natriuretic peptides measurements in the diagnostics of chosen cardiovascular diseases. Pol Merkur Lekarski. 34:232–234. 2013.PubMed/NCBI
25	Halawa B: Plasma adrenomedullin concentration in patients with essential hypertension. Pol Merkur Lekarski. 5:111–113. 1998.PubMed/NCBI